<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Vertex Pharmaceuticals Inc — News on 6ix</title>
    <link>https://6ix.com/company/vertex-pharmaceuticals-inc</link>
    <description>Latest news and press releases for Vertex Pharmaceuticals Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 28 Apr 2026 13:02:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/vertex-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d3d178dffbe2df120b82.webp</url>
      <title>Vertex Pharmaceuticals Inc</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc</link>
    </image>
    <item>
      <title>A Call to Action to Help Fight Kidney Failure in At-Risk Communities:  American Kidney Fund Urges People to be APOL1 Aware</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/a-call-to-action-to-help-fight-kidney-failure-in-at-risk-communities-american-kidney-fund-urges-people-to-be-apol1-aware</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/a-call-to-action-to-help-fight-kidney-failure-in-at-risk-communities-american-kidney-fund-urges-people-to-be-apol1-aware</guid>
      <pubDate>Tue, 28 Apr 2026 13:02:00 GMT</pubDate>
      <description>Newly established AMKD Coalition unites leading voices to address need to heighten awareness of APOL1-mediated kidney disease (AMKD)ROCKVILLE, Md., April 28, 2026 (GLOBE NEWSWIRE) -- Today marks the third annual APOL1-Mediated Kidney Disease (AMKD) Awareness Day, a day established by the American Kidney Fund (AKF) to encourage others to be “APOL1 Aware” by educating communities about this genetic form of rapidly progressing kidney disease. Support for AMKD Awareness Day is provided by Vertex Pha</description>
    </item>
    <item>
      <title>Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/halozyme-announces-global-collaboration-and-license-agreement-with-vertex-pharmaceuticals-for-hypercontm-technology-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/halozyme-announces-global-collaboration-and-license-agreement-with-vertex-pharmaceuticals-for-hypercontm-technology-1</guid>
      <pubDate>Tue, 07 Apr 2026 12:00:00 GMT</pubDate>
      <description>Halozyme Therapeutics, Inc. (Nasdaq: HALO) (&quot;Halozyme&quot; or the &quot;Company&quot;) today announced its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals Incorporated (&quot;Vertex&quot;). Under the collaboration, Vertex has licensed Halozyme&apos;s Hypercon™ technology for use in up to three drug targets. Hypercon™ is an innovative microparticle technology that allows for hyperconcentration of drugs and biologics, thus reduci</description>
    </item>
    <item>
      <title>Vertex to Announce First Quarter 2026 Financial Results on May 4th</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-to-announce-first-quarter-2026-financial-results-on-may-4th-1</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-to-announce-first-quarter-2026-financial-results-on-may-4th-1</guid>
      <pubDate>Mon, 06 Apr 2026 20:00:00 GMT</pubDate>
      <description>BOSTON, April 06, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2026 financial results on Monday, May 4, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the &quot;Vertex Pharmaceuticals First Quarter 2026 Earnings Call.&quot;</description>
    </item>
    <item>
      <title>Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-announces-us-fda-approval-for-label-extensions-of-alyftrekr-and-trikaftar-expanding-availability-of-these-medicines-to-95percent-of-all-people-with-cf-in-the-united-states</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-announces-us-fda-approval-for-label-extensions-of-alyftrekr-and-trikaftar-expanding-availability-of-these-medicines-to-95percent-of-all-people-with-cf-in-the-united-states</guid>
      <pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
      <description>-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the</description>
    </item>
    <item>
      <title>Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-announces-positive-week-36-interim-analysis-results-for-primary-and-all-secondary-endpoints-in-the-rainier-phase-3-trial-of-povetacicept-in-adults-with-iga-nephropathy-18</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-announces-positive-week-36-interim-analysis-results-for-primary-and-all-secondary-endpoints-in-the-rainier-phase-3-trial-of-povetacicept-in-adults-with-iga-nephropathy-18</guid>
      <pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
      <description>- For the primary endpoint, patients treated with povetacicept achieved a 52.0% reduction from baseline in proteinuria as measured by 24-hour urine protein</description>
    </item>
    <item>
      <title>Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-to-present-new-data-on-journavxr-that-demonstrates-effective-pain-management-following-aesthetic-and-reconstructive-procedures-3</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-to-present-new-data-on-journavxr-that-demonstrates-effective-pain-management-following-aesthetic-and-reconstructive-procedures-3</guid>
      <pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
      <description>-Over 90% of patients in the study were opioid free through the end of multimodal treatment with JOURNAVX- -These data have been accepted for oral</description>
    </item>
    <item>
      <title>Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-to-participate-in-td-cowen-46th-annual-health-care-conference-on-march-3</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-to-participate-in-td-cowen-46th-annual-health-care-conference-on-march-3</guid>
      <pubDate>Tue, 17 Feb 2026 21:00:00 GMT</pubDate>
      <description>BOSTON, February 17, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in TD Cowen’s 46th Annual Health Care Conference. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Tuesday, March 3, 2026, at 9:10 a.m. ET.</description>
    </item>
    <item>
      <title>Vertex Reports Fourth Quarter and Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-reports-fourth-quarter-and-full-year-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
      <pubDate>Thu, 12 Feb 2026 21:01:00 GMT</pubDate>
      <description>BOSTON, February 12, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2025, and provided its full year 2026 financial guidance.</description>
    </item>
    <item>
      <title>WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/wuxi-biologics-and-vertex-sign-license-and-research-service-agreement-for-t-cell-engager</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/wuxi-biologics-and-vertex-sign-license-and-research-service-agreement-for-t-cell-engager</guid>
      <pubDate>Mon, 02 Feb 2026 05:00:00 GMT</pubDate>
      <description>SHANGHAI, Feb. 2, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO),</description>
    </item>
    <item>
      <title>Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-announce-fourth-quarter-and-full-year-2025-financial-results-february-12th</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-announce-fourth-quarter-and-full-year-2025-financial-results-february-12th</guid>
      <pubDate>Tue, 20 Jan 2026 05:00:00 GMT</pubDate>
      <description>BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2025 financial results on Thursday,</description>
    </item>
    <item>
      <title>Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-provides-pipeline-and-business-updates-advance-upcoming-investor-meetings-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-provides-pipeline-and-business-updates-advance-upcoming-investor-meetings-2026</guid>
      <pubDate>Sun, 11 Jan 2026 05:00:00 GMT</pubDate>
      <description>BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor meetings</description>
    </item>
    <item>
      <title>Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-present-44th-annual-jp-morgan-healthcare-conference-january-12-2025-12-22</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-present-44th-annual-jp-morgan-healthcare-conference-january-12-2025-12-22</guid>
      <pubDate>Mon, 22 Dec 2025 05:00:00 GMT</pubDate>
      <description>BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and</description>
    </item>
    <item>
      <title>Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-presents-new-data-casgevyr-including-first-ever-data-children-ages-5-11-years</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-presents-new-data-casgevyr-including-first-ever-data-children-ages-5-11-years</guid>
      <pubDate>Sat, 06 Dec 2025 05:00:00 GMT</pubDate>
      <description>- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the</description>
    </item>
    <item>
      <title>Vertex to Participate in the Citi’s 2025 Global Healthcare Conference on December 3</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-participate-citis-2025-global-healthcare-conference-december-3-2025-11-19</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-participate-citis-2025-global-healthcare-conference-december-3-2025-11-19</guid>
      <pubDate>Wed, 19 Nov 2025 05:00:00 GMT</pubDate>
      <description>BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in Citi’s 2025 Global Healthcare</description>
    </item>
    <item>
      <title>Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-presents-updated-phase-1-2-data-ruby-3-study-continue-demonstrate-best-class</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-presents-updated-phase-1-2-data-ruby-3-study-continue-demonstrate-best-class</guid>
      <pubDate>Sat, 08 Nov 2025 05:00:00 GMT</pubDate>
      <description>- 48-week data show a 64% decrease from baseline in proteinuria in IgA nephropathy, 82% decrease from baseline in proteinuria in primary membranous</description>
    </item>
    <item>
      <title>Vertex Reports Third Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-reports-third-quarter-2025-financial-results-2025-11-03</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-reports-third-quarter-2025-financial-results-2025-11-03</guid>
      <pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
      <description>— Total revenue of $3.08 billion, an 11% increase compared to Q3 2024 — — Refined full year financial guidance: total revenue guidance now $11.9 to $12.0</description>
    </item>
    <item>
      <title>Vertex to Participate in the UBS Global Healthcare Conference on November 11</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-participate-ubs-global-healthcare-conference-november-11-2025-10-27</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-participate-ubs-global-healthcare-conference-november-11-2025-10-27</guid>
      <pubDate>Mon, 27 Oct 2025 04:00:00 GMT</pubDate>
      <description>BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the UBS Global Healthcare</description>
    </item>
    <item>
      <title>Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-presents-new-data-across-portfolio-cystic-fibrosis-medicines-including</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-presents-new-data-across-portfolio-cystic-fibrosis-medicines-including</guid>
      <pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
      <description>- Data presented on outcomes following treatment with CFTR modulators add to growing body of evidence that reduced level of sweat chloride is associated with</description>
    </item>
    <item>
      <title>Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-announces-progress-povetacicept-development-program-and-presentation-new-data</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/vertex-announces-progress-povetacicept-development-program-and-presentation-new-data</guid>
      <pubDate>Fri, 17 Oct 2025 04:00:00 GMT</pubDate>
      <description>- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module</description>
    </item>
    <item>
      <title>Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors</title>
      <link>https://6ix.com/company/vertex-pharmaceuticals-inc/news/odyssey-therapeutics-appoints-pharmaceutical-leader-nia-tatsis-phd-to-its-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/vertex-pharmaceuticals-inc/news/odyssey-therapeutics-appoints-pharmaceutical-leader-nia-tatsis-phd-to-its-board-of-directors</guid>
      <pubDate>Thu, 09 Oct 2025 12:00:00 GMT</pubDate>
      <description>BOSTON, October 09, 2025--Odyssey announces appointment of Nia Tatsis, Ph.D., EVP of Vertex Pharmaceuticals, to its Board of Directors.</description>
    </item>
  </channel>
</rss>